VELOUR

NCT00561470 📎

Regimen

Experimental
Ziv-aflibercept (aflibercept) 4 mg/kg Q2W + FOLFIRI
Control
Placebo + FOLFIRI

Population

Metastatic CRC, 2L, after progression on oxaliplatin-containing regimen (including bevacizumab-pretreated patients).

Key finding

2L mCRC (post-oxaliplatin): mOS 13.50 vs 12.06 mo (HR 0.817, 95% CI 0.713-0.937, p=0.0032); mPFS 6.90 vs 4.67 mo (HR 0.758, 95% CI 0.661-0.869, p<0.0001); ORR 19.8% vs 11.1% (p=0.0001); benefit consistent in bevacizumab-pretreated subgroup

Source: PMID 22949147

Timeline

    Guideline citations

    • NCCN Colon (p.20)
    • NCCN Rectal (p.26)